-
First-line immunotherapy for head and neck cancer! AstraZenecom anti-PD-L1 therapy Imfinzi (Infinfan) Phase 3 clinical failure!
Time of Update: 2021-02-27
KESTREL is a randomized, open-label, multi-center, global Phase 3 trial conducted in patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) who had not previously been treated, evaluating the efficacy and safety of the anti-CTLA-4 immunotherapy tremelimumab for first-line treatment and comparing it with standard care program EXTREME (chemotherapy and syxidiosis).
-
Mol Cell: Revealing the previously unknown dual functions of polymerases that are important for cancer growth promises to help develop new cancer therapies
Time of Update: 2021-02-27
'The polymerase pol theta is a "hot spot" enzyme, and we describe a new activity that may help develop new therapeutic options for patients with refractive cancer, such as the use of PARP inhibitors to treat breast and ovarian cancer,' said Dr. Sylvie Typié, a researcher at University of Vermont.
-
Br J Cancer: Analysis of survival rates in breast cancer patients with BRCA2 mutations
Time of Update: 2021-02-26
previous studies have shown that most breast cancers associated with BRCA2 mutations show ER-positive, while ER-positive is a favorable prognostic factor compared to ER-negative in the general early-stage patient population.
-
Br J Cancer: Multigene testing guides chemotherapy recommendations for breast cancer
Time of Update: 2021-02-26
Therefore, the study aims to develop health care recommendations on whether the use of multigene testing can guide the development of complementary chemotherapy in patients with early-stage immersive breast cancer, hormone-positive, HER2-negative patients.
-
Clin Cancer Res: Hedgehog signal suppression changes the composition of fibroblasts and immune cell immersion that alters the microencular environment of pancreatic cancer
Time of Update: 2021-02-26
the Hedgehog path pathland works in PDAC in a side secretion manner, and the mediates secreted by cancer cells signal to the substring cells in the micro-environment.
-
Nasopharyngeal cancer immunotherapy! Junshi bio-anti-PD-1 therapy Terripri monoanti (toyo®) and chemotherapy first-line treatment application was accepted by NMPA!
Time of Update: 2021-02-26
29 February 2021 / -- TopAlliance Biosciences recently announced that the National Drug Administration (NMPA) has accepted its own A new adaptive application for the developed anti-PD-1 monoantigen drug Terripri monoantigen (Toripalimab®): combined chemotherapy for relapsed metastatic nasopharyngeal cancer (NPC) in advanced first-line unsyscticed treatment.
-
JAMA Netw Open: High dietary fiber, calcium and yogurt can reduce the incidence of colorectal cancer
Time of Update: 2021-02-26
, a recent study published in JAMA Netw Open showed that higher dietary fiber, calcium and yogurt, as well as lower alcohol and red meat intake, reduced the risk of CRC.
-
Lancet: Compared to the efficacy of three MET kinase inhibitors for metastatic pap-shaped renal cell carcinoma
Time of Update: 2021-02-26
patients were randomly assigned to receive shonitinib, carbotinib, clotinib, or savolitinib, strated according to past treatment history and PRCC subsype.
, metastasis PRCC patients received significantly longer PFS after treatment with cabotinib than Schoini.
-
Nat Med: A summary analysis of pathological response and survival rates of new complementary therapies for melanoma
Time of Update: 2021-02-25
in patients with stage IV melanoma, immunotherapy based on anti-PD-1 and BRAF/MEK combined target therapies had higher response rates and improved overall survival (OS).
-
ASCO GU 2021: The efficacy of the combined treatment of metastatic renal cell carcinoma with Navuliyu monoanti- and Ipi-anti-anti-drugs
Time of Update: 2021-02-25
At present, the combination of Navuliyu monoanti-Ipi monoanti and vascular endodermal growth factor (VEGF) inhibitor immunotherapy is a first-line treatment for metastatic renal cell carcinoma (mRCC).
-
J Clin Oncol: Do patients with stage IV colorectal cancer who have underwent a distant metastasis need to have their primary tumor removed before chemotherapy?
Time of Update: 2021-02-25
But for patients with both asymptomatic primary tumors and metastatic lesions that cannot be removed, the initial treatment option is still controversial, mainly about whether removing primary tumors (PTRs) before chemotherapy can improve the survival rate of such patients.
-
The European Union approved Tukysa for the treatment of HER2-positive localized advanced or metastasis breast cancer
Time of Update: 2021-02-25
in the HER2CLIMB trial at Tukysa in Seagen, TKI and cratur bead monoantigen and carpedabin used to reduce the risk of disease progress in patients by 46%.
survival of patients in the Tukysa combined treatment group was also improved, with a 34 percent reduction in the risk of death.
-
Nat Commun: Chromatin accessability of circulating CD8-T cells predicts the response of gastric cancer patients to PD-1 therapy
Time of Update: 2021-02-25
although tumor genomic analysis has identified a small percentage of patients with stomach cancer (GC) who could benefit from anti-PD-1 treatment, not all reactions can be explained by tumor sequencing alone.
-
ASCO GU 2021: Analysis of the efficacy of the treatment of non-metastatic despotable prostate cancer
Time of Update: 2021-02-25
ARAMIS test results showed that dalorumamine had no metastasis lifetime (PFS) improvement in NM-CRPC patients.
-
JAMA sub-journal: More than 60% of cancer deaths are attributable to occupational carcinogen exposure, especially asbestos and silicon dioxide
Time of Update: 2021-02-25
results show that occupational carcinogen (OCs) exposure is the cause of global cancer deaths and DALY, and that the relative cancer burden varies widely from region to region, depending on age, gender and social development.
-
Clin Cancer Res: Pym single-drug treatment PD-L1 combined positive score≥10 efficacy of gastric/gastroesophageal junction cancer
Time of Update: 2021-02-25
patients in the KEYNOTE-062 trial had a prognosis of 11 months in KEYNOTE-062, and the middle OS in the Pym monoantial and chemotherapy groups was 17 months vs 11 months (HR 0.69; 95% CI 0.49 to 0.97), and the middle was PFS is 3 months vs 6 months (HR 1.09, 95% CI 0.79 to 1.49), ORR is 25% vs 38%, and the middle DOR (range) is 19 months (1 to 34 plus) vs 7 months (2 to 30 plus).
-
Clin Cancer Res: DNA methyl transferase inhibitor Guadecitabine combined with cisplatin and giscitabine to treat solid malignancies
Time of Update: 2021-02-25
the dose increment phase at the dose increment stage, dose-limiting toxicity is mainly related to the bone marrow inhibition that queue 2 requires G-CSF to prevent (guadecitabine 20 mg/m2, 1-5 days).
, guadecitabine combined with Giscitabine and Shunplain RP2D is 20 mg/m2 for 1st to 5th days and requires G-CSF to prevent bone marrow inhibition.
-
Toilet phobia? The 57-year-old aunt every time she went to the toilet headache and burst her blood pressure, she was hiding the tumor
Time of Update: 2021-02-24
" Yang big sister at home near the hospital again took blood pressure, but the results showed very normal, after Yang big sister explained the recent headache symptoms, the doctor suspected that she may be suffering from a disease called chromosoma, then suggested that she do an adrenal CT and epinephrine, epinephrine level test.
-
ASCO GU 2021: Updated results of postoperative assisted chemotherapy Phase III POUT trial results for upper urinary tract tract skin cancer
Time of Update: 2021-02-24
Birtle summed up the latest analysis of phase III clinical trials in POUT and concluded that the benefits of complementary chemotherapy for disease-free and metastasis-free survival were maintained through additional follow-up.
-
JAMA Oncol: 22 Gene Genome Classifiers predict the risk of distant metastasis after prostate cancer!
Time of Update: 2021-02-24
in multivariate analysis, GC and DM (risk ratio 1.17; 95% CI 1.05-1.32; P-0.22; P-0.2) were calibrated by age, race/ethnicity, Gleason score, T-phase, cut-off state, prostate-specific antigen and treatment.
